MIT China files for Chinese FDA approval after successful completion of its second local clinical trial

DENVER, CO, Aug. 11 /PRNewswire-FirstCall/ - Medical International Technology Inc. (MDLH.OB) www.mitneedlefree.com is pleased to announce its progress in China.

The first clinical trial required towards obtaining the Chinese FDA approval was completed last June. The second and final trial was recently completed successfully and MIT China received the final report from the two hospitals involved in the trial. The complete report has been submitted to the Chinese FDA authorities for final approval and issuance of the official licence to sell MIT Med-Jets, which is anticipated to begin within 4 to 6 weeks.

MIT President and CEO, Mr Karim Menassa would like to officially congratulate his Chinese partners, all the employees of MIT China, as well as all the dedicated people that helped us reach such a challenging and important milestone in a very short time. MIT now anticipates sales to grow at a fast pace starting in November 2010.

Vice-President and Chief Strategic Officer, Dr Francis Bellido said: "The first accomplishment of the company's three priorities for 2010 will increase our visibility and raise awareness about MIT Canada's unique needle-free technology and products. Moreover, our second and third priorities are underway with completion expected by the end of 2010".

Mr. Harold Gervais, CFO of MIT has completed his mandate and realized the main objectives assigned to him when he joined MIT on a part time basis in January 2010. Mr Gervais will remain on the advisory board and will be available to head various initiatives as the company grows.

Medical International Technology Inc. is proud to continue providing a safe and effective means to help prevent the spread of deadly diseases to both humans and animals through the use of the Med-Jet(R) and Agro-Jet(R) needle-free injection system.

About Medical International Technology, Inc. MIT CANADA, with offices in Montreal, is a subsidiary of Denver, Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass vaccinations.

The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development and acquisition of new product lines and services, government approval processes, the impact of competitive products or pricing a technological changes, the effect of economic conditions and other uncertainties, and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. Medical International Technology Inc. takes no obligation to update or correct forward-looking statements.

SOURCE MEDICAL INTERNATIONAL TECHNOLOGIES INC.